John C. Panetta

9.4k total citations · 1 hit paper
161 papers, 6.6k citations indexed

About

John C. Panetta is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, John C. Panetta has authored 161 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 63 papers in Public Health, Environmental and Occupational Health and 53 papers in Molecular Biology. Recurrent topics in John C. Panetta's work include Acute Lymphoblastic Leukemia research (62 papers), Cancer therapeutics and mechanisms (33 papers) and Childhood Cancer Survivors' Quality of Life (31 papers). John C. Panetta is often cited by papers focused on Acute Lymphoblastic Leukemia research (62 papers), Cancer therapeutics and mechanisms (33 papers) and Childhood Cancer Survivors' Quality of Life (31 papers). John C. Panetta collaborates with scholars based in United States, India and Canada. John C. Panetta's co-authors include Denise E. Kirschner, Mary V. Relling, Ching‐Hon Pui, Clinton F. Stewart, William E. Evans, K. Renee Fister, Deqing Pei, Wenjian Yang, Cheng Cheng and John Adam and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

John C. Panetta

153 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Modeling immunotherapy of the tumor - immune interaction

1998 678 citations John C. Panetta et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John C. Panetta United States	44	2.3k	2.1k	2.0k	1.6k	1.2k	161	6.6k
Nicolás André France	50	2.8k 1.2×	357 0.2×	4.1k 2.0×	418 0.3×	383 0.3×	264	8.6k
Clinton F. Stewart United States	63	5.1k 2.2×	733 0.3×	6.1k 3.0×	1.3k 0.8×	96 0.1×	317	12.0k
Branimir I. Šikić United States	57	4.9k 2.1×	434 0.2×	4.7k 2.3×	872 0.5×	21 0.0×	225	9.6k
Andrew Berchuck United States	73	5.8k 2.5×	1.0k 0.5×	8.1k 4.0×	403 0.3×	30 0.0×	358	19.9k
Paolo Vicini United States	34	613 0.3×	217 0.1×	1000 0.5×	165 0.1×	245 0.2×	127	3.8k
Serge Koscielny France	42	1.8k 0.8×	212 0.1×	1.8k 0.9×	142 0.1×	48 0.0×	135	5.7k
David Schiff United States	69	2.8k 1.2×	186 0.1×	4.5k 2.2×	753 0.5×	136 0.1×	373	16.9k
Joseph Ciccolini France	36	2.4k 1.0×	150 0.1×	1.6k 0.8×	93 0.1×	374 0.3×	196	4.5k
David B. Agus United States	47	2.2k 0.9×	156 0.1×	3.9k 1.9×	86 0.1×	147 0.1×	116	8.0k
John G. Kuhn United States	55	3.4k 1.5×	242 0.1×	3.8k 1.9×	226 0.1×	40 0.0×	188	8.8k

Countries citing papers authored by John C. Panetta

Since Specialization

Citations

This map shows the geographic impact of John C. Panetta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Panetta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Panetta more than expected).

Fields of papers citing papers by John C. Panetta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Panetta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Panetta. The network helps show where John C. Panetta may publish in the future.

Co-authorship network of co-authors of John C. Panetta

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Panetta. A scholar is included among the top collaborators of John C. Panetta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Panetta. John C. Panetta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yarur, Andrés, Thierry Dervieux, Ryan C. Ungaro, et al.. (2025). Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease. Pharmaceutics. 17(2). 187–187.

Panetta, John C., Uday Kulkarni, Balaji Balakrishnan, et al.. (2023). Treosulfan Exposure Predicts Thalassemia‐Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical Pharmacology & Therapeutics. 115(1). 116–125. 2 indexed citations

Primas, Christian, Walter Reinisch, John C. Panetta, et al.. (2022). Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. Journal of Clinical Medicine. 11(12). 3316–3316. 10 indexed citations

Budhraja, Amit, J.A. Lynch, Kathryn G. Roberts, et al.. (2020). The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics. Molecular Cancer Research. 19(4). 636–650. 12 indexed citations

López-López, Elixabet, Robert J. Autry, Colton Smith, et al.. (2020). Pharmacogenomics of intracellular methotrexate polyglutamates in patients’ leukemia cells in vivo. Journal of Clinical Investigation. 130(12). 6600–6615. 20 indexed citations

Inaba, Hiroto, John C. Panetta, Stanley Pounds, et al.. (2019). Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clinical Cancer Research. 25(24). 7320–7330. 15 indexed citations

Budhraja, Amit, Meghan E. Turnis, Michelle L. Churchman, et al.. (2017). Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia. Clinical Cancer Research. 23(24). 7558–7568. 25 indexed citations

Pauley, Jennifer L., John C. Panetta, Deqing Pei, et al.. (2016). Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. Journal of Pediatric Hematology/Oncology. 38(6). 449–452. 15 indexed citations

Bhojwani, Deepa, Noah D. Sabin, Deqing Pei, et al.. (2014). Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 32(9). 949–959. 242 indexed citations

10.

Broniscer, Alberto, Sharyn D. Baker, Cynthia Wetmore, et al.. (2013). Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research. 19(11). 3050–3058. 74 indexed citations

11.

Ramsey, Laura B., John C. Panetta, Colton Smith, et al.. (2012). Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 121(6). 898–904. 157 indexed citations

12.

Pauley, Jennifer L., Alejandro R. Molinelli, John C. Panetta, et al.. (2012). Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer. 118(17). 4321–4330. 61 indexed citations

13.

Panetta, John C., Maryam Fouladi, Amar Gajjar, et al.. (2010). Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma. Clinical Cancer Research. 16(3). 1049–1057. 11 indexed citations

14.

Kawedia, Jitesh D., Sue C. Kaste, Deqing Pei, et al.. (2010). Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 117(8). 2340–2347. 186 indexed citations

15.

Shen, Jun, Ángel M. Carcaboso, Karen Hubbard, et al.. (2009). Compartment-Specific Roles of ATP-Binding Cassette Transporters Define Differential Topotecan Distribution in Brain Parenchyma and Cerebrospinal Fluid. Cancer Research. 69(14). 5885–5892. 42 indexed citations

16.

Furman, Wayne L., Fariba Navid, Najat C. Daw, et al.. (2009). Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology. 27(27). 4599–4604. 42 indexed citations

17.

Yang, Lei, John C. Panetta, Xiangjun Cai, et al.. (2008). Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 26(12). 1932–1939. 107 indexed citations

18.

Schaiquevich, Paula, John C. Panetta, Lisa Iacono, et al.. (2007). Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients. Clinical Cancer Research. 13(22). 6703–6711. 16 indexed citations

19.

Hijiya, Nobuko, John C. Panetta, Yinmei Zhou, et al.. (2006). Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 108(13). 3997–4002. 85 indexed citations

20.

Kager, Leo, Meyling Cheok, Wenjian Yang, et al.. (2005). Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation. 115(1). 110–117. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact